NasdaqGS:LEGNBiotechs
How Investors Are Reacting To Legend Biotech (LEGN) Carvykti-Fueled Revenue Surge And Narrowing Losses
Legend Biotech’s past first-quarter 2026 results showed revenue rising to US$305.1 million from US$195.0 million a year earlier, while net loss narrowed to US$54.3 million from US$101.0 million, driven largely by higher Carvykti-related collaboration revenue and broader international availability.
Beyond the headline miss versus analyst forecasts, the earnings update underscored Carvykti’s expanding global footprint across 18 countries and improving operating performance that reduced losses,...